TY - JOUR
T1 - Melatonin treatment improves primary progressive multiple sclerosis
T2 - A case report
AU - Lõpez-González, Antonio
AU - Álvarez-Sánchez, Nuria
AU - Lardone, Patricia J.
AU - Cruz-Chamorro, Ivan
AU - Martínez-Lõpez, Alicia
AU - Guerrero, Juan M.
AU - Reiter, Russel J.
AU - Carrillo-Vico, Antonio
PY - 2015/3
Y1 - 2015/3
N2 - We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.
AB - We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.
KW - melatonin
KW - multiple sclerosis
KW - primary progressive multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=84922785909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922785909&partnerID=8YFLogxK
U2 - 10.1111/jpi.12203
DO - 10.1111/jpi.12203
M3 - Article
C2 - 25546814
AN - SCOPUS:84922785909
VL - 58
SP - 173
EP - 177
JO - Journal of Pineal Research
JF - Journal of Pineal Research
SN - 0742-3098
IS - 2
ER -